Skip to main content
Premium Trial:

Request an Annual Quote

Dynacare Labs to Offer Visible Genetics HIV Genotyping Kit in North America

NEW YORK, Dec. 18 — Dynacare, the clinical lab services company, will soon offer Visible Genetics' TRUGENE HIV-1 genotyping test in its central labs and local patient-service centers in the US and Canada, the groups announced late Monday.

 

The test uses a genotype report to identify variant strains of HIV, which allows for more accurate and effective drug therapy. Since the virus mutates rapidly and many strains are resistant to many of the first-order antiviral drugs, genotyping tests can streamline the drug-selection process.

 

The kit, approved by the US Food & Drug Administration in September, is the only HIV drug resistance test on the market, Dynacare said.

 

The company will offer the test in its 22 central labs, its 63 so-called rapid-response labs, and its 173 patient-service centers at a cost of $700, said Judi Ottmann, Dynacare's associate vice president for marketing. She added that several major insurance companies have already agreed to cover the test in their policies, and that Dynacare is actively involved in getting others to make the same pledge.

 

Visible Genetics, headquartered in Toronto, markets high performance DNA sequencing systems and gene analysis kits.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.